[Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Ceska R;Ceska R; Stulc T
  • Source:
    Casopis lekaru ceskych [Cas Lek Cesk] 2000 Jun 21; Vol. 139 (12), pp. 369-73.
  • Publication Type:
    Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    Czech
  • Additional Information
    • Transliterated Title:
      Fenofibrate 250 SR Pharmavit u nemocných se smísenou hyperlipoproteinémií. Výsledky sledování u 189 nemocných ze 13 center v CR.
    • Source:
      Publisher: Ceskoslovenska Lekarska Spolecnost Country of Publication: Czech Republic NLM ID: 0004743 Publication Model: Print Cited Medium: Print ISSN: 0008-7335 (Print) Linking ISSN: 00087335 NLM ISO Abbreviation: Cas Lek Cesk Subsets: MEDLINE
    • Publication Information:
      Original Publication: Praha : Ceskoslovenska Lekarska Spolecnost
    • Subject Terms:
      Fenofibrate/*therapeutic use ; Hyperlipoproteinemias/*drug therapy ; Hypolipidemic Agents/*therapeutic use; Female ; Fenofibrate/adverse effects ; Humans ; Hyperlipoproteinemias/blood ; Hypolipidemic Agents/adverse effects ; Lipids/blood ; Male ; Middle Aged
    • Abstract:
      Background: Hyperlipoproteinemia represents one of the major risk factors in the early atherosclerosis manifestation, namely in the ischaemic heart disease. In patients after the myocardial infarction, mixed hyperlipoproteinemia becomes the most frequently diagnosed impairment of the lipid metabolism. In the therapy, fibrates begin to play an important role. A new remedy containing micronised fenofibrate (Fenofibrate 250 SR Pharmavit) was recently registered for the Czech market. The aim of our study was to test its effects in almost 200 patients with mixed hyperlipoproteinemia.
      Methods and Results: Into statistical analysis of the treatment effectiveness 187 persons (115 males, 72 females) were included. Other characteristics of the studied group (mean +/- SD): age 54.0 +/- 10.7 years, stature 172.0 +/- 8.7 cm, weight, BMI 28.0 +/- 3.1. Prevalence of risk factors and clinical manifestations of the atherosclerosis: ICHS 18.2%, myocardial infarction 7.5%, ICHDK 4.3%, CMP 5.3%, smoking 27.8%, arterial hypertension 63.6%, diabetes mellitus 17.6%, positive family history in ICHS 50.3%. 44.9% persons had been treated with hypolipidemics. Basic parameters of the lipid metabolism, cholesterol, LDL and HDL cholesterol and triglycerides were studied. Plasma levels of uric acid, fibrinogen, glucose and other biochemical parameters were also used to monitor the safeness of the treatment. Cholesterol concentration (7.05 +/- 0.91 mmol/l) decreased (6.14 +/- 0.89 mmol/l) almost by 15%. Triglyceride concentration decrease (from 4.43 +/- 1.84 mmol/l to 2.64 +/- 1.34 mmol/l) was more intensive (41%). HDL-cholesterol increased by almost 15%, while LDL-cholesterol decreased by 12%. Statistically significantly decreased level of the uric acid (12%), fibrinogene decrease (8.4%) reached only marginal significance. Treatment was well tolerated, only in one patient it was necessary to cut it prematurely.
      Conclusions: According clinical tests which included almost 200 patients with mixed hyperlipoproteinemia, Fenofibrate 250 SR Pharmavit stands for an effective and well tolerated hypolipidemics.
    • Accession Number:
      0 (Hypolipidemic Agents)
      0 (Lipids)
      U202363UOS (Fenofibrate)
    • Publication Date:
      Date Created: 20000823 Date Completed: 20001019 Latest Revision: 20131121
    • Publication Date:
      20250114
    • Accession Number:
      10953407